Studies of T cell-mediated immune response against spontaneously arising autologous human tumors have been markedly facilitated by functional analyses of T cells at the clonal level (1-7). This particular approach has now provided a strong support for the long-held belief by some, although viewed skeptically by others, that T cell-mediated host responses do indeed exist in different types ofhuman cancers. The evidence for such T cell antitumor response has been particularly impressive in malignant melanoma (1-4, 6, 7). In this system, the existence of CTL response (1-4, 6, 7), proliferative T cell response (8, 9), suggestion for regulatory T cell response (10, 11), and delayed-type hypersensitivity response (12) have all been demonstrated. While this impressive body of evidence certainly represents a serious beginning in investigation on T cell responses against autologous cancer, a critical analysis ofT cell-immune responses against a large number ofautologous melanoma at clonal levels is necessary for a more comprehensive understanding of T cell-immune response in host defense against human cancers or, for that matter, against malignant melanoma .
Assayfor Regulation of Cytotoxicity. The basic in vitro assay to examine cell-mediated regulation of cytotoxic response in in vitro coculture has been published earlier (10, 11, 13) . Briefly, to assay regulation of generation of cytotoxicity in the PBL (at induction phase), standard in vitro activation cocultures between PBL and irradiated targets (3,000 rad) were set up in the presence or in the absence of irradiated (3,000 rad) cloned lymphocytes as potential regulatory cells at different PBL to regulatory cell ratios. Cytotoxicity was assayed on day 7 at different E/T ratios. Percent enhancement and percent suppression were calculated with the following formulas: percent suppression = 100 x [1 -(percent specific lysis with regulatory cells)/(percent specific lysis without regulatory cells)] ; percent enhancement = 100 x [1 -(percent specific lysis without regulatory cells)/(percent specific lysis with regulatory cells)] . Mean cpm of three replicate samples from wells containing the E/T ratio of 20 :1 was used to calculate percent changes . To assay potential regulation ofcytotoxicity at the effector phase, cytotoxiciy of the CTL clones was assayed in the presence or absence of autologous sera or of PBL as potential regulatory cells .
Results
Cytotoxic Response Against Autologous Target Cells. Fig. 1 shows representative examples ofcytolytic responses by the freshly derived and in vitro activated autologous PBL or LNL in three autologous melanoma systems . In none ofthese three systems were the fresh PBL or LNL cytotoxic against the respective autologous targets . In two cases, the activated effectors, however, exhibited significant levels of cytotoxicity against the autologous targets. In a composite analysis of 31 autologous systems, the freshly derived PBL or LNL were marginally cytotoxic against the autologous targets in only two cases . In 19 of 31 cases, the activated effector cells (PBL, LNL, or both) exhibited significant cytotoxicity (> ,10 LU 1,000/106 effector cells) (combined data not shown). In continuous culture the cytotoxic responses by the effector cells usually reached their peak levels by 2-3 wk and declined to the base line levels by the 5th to 7th week (data not shown) . Restimulation with autologous melanoma cells as antigen and PBL or spleen cells (whenever available) as accessory cells helped the cytotoxic activity to rebound somewhat, but seldom to their earlier peak levels (data not shown) . Although differences in the cytotoxic response (ranging from minor to marked) between autologous PBL and LNL was observed in several cases, cytotoxic unresponsiveness did not reside exclusively, however, with the PBL or with the LNL (composite data not shown) .
The cytotoxic responses by the activated PBL or LNL were almost always seen Cytotoxicity by the fresh PBL (O) and by the activated PBL (0) against the corresponding autologous melanoma cells. Cytotoxicities of the activated PBL were tested at 2 wk after the initiation of IVC.
against a broad range of target cells, including the NK-sensitive target, K-562 . The activated PBL or LNL usually contained both CD4+ and CD8+ populations, although in some cases there was a significant preponderance of one subset or another. For example, in the DM system (Fig. 1) , the activated PBL were predominantly CD4+ (80%); whereas, in the PT system, they were predominantly CD8 + (90%). Fig. 2 shows the cytotoxic profiles of three CD8+ clones in the PT system . In this system, clone A15 demonstrated a broad range of cytotoxic activity ; while clone PT 32 was noncytotoxic. Clone PT 31, on the other hand, exhibited cytotoxicity that was restricted against the autologous target PTIM . All three clones were phenotypically identical (CD3 + , CD8+, CD4-, Ia+), and the two cytotoxic clones (PT 31 and A15) required periodic (every 1-2 wk) stimulation with the autologous melanoma cells PTIM with or without autologous PBL or splenocytes (irradiated to 3,000 rad) for maintenence of their cytotoxic functions. Unstimulated cultures rapidly lost cytotoxic function . Fig. 3 shows the cytotoxic profiles of four CTL clones that were derived from activated PBL or LNL from four separate cases. Clone PT 31 and RN C8 were derived from activated PBL; whereas, the other two clones were derived from activated LNL from melanoma-involved lymph nodes. All four clones expressed identical pheno- tt t ~y t t t t t t type (CD3+, CD8+, CD4 -, WT31+, and HNKI -), and all lysed the respective autologous melanoma cells in a restricted fashion. The CTL clone RN C8 could not be maintained in continuous culture long enough to perform more detailed analyses . The other three clones grew for a long enough time to allow more detailed analyses . The restricted specificities for the respective autologous melanoma cells were confirmed in cold target competition assays in two systems. In both systems, only the autologous melanoma cells avidly competed with the corresponding labeled autologous melanoma cells for the corresponding CTL receptors (Fig . 4) . Three CTL clones (clone Tcl.8 in the VIP system, clone PT 31 in the PT system, and clone MCC5 in the MC system) demonstrated MHC class I-restricted killing, while clone RN C8 in the RN system showed no MHC restriction (Table I) .
To analyze the broad target range of the cytotoxic behavior of clone A15 in the PT system, we carried out its specificity analysis in cold target competition assay. Interestingly, in cytotoxic interaction between clone A15 and the autologous PTIM (Fig . 5) . Conversely, against an allogeneic target (FP-M), which was lysed quite well by A15, no competition between the relevant autologous melanoma cells and the allogeneic targets, or between the irrelevant allogeneic targets, was noted ( Fig . 5 ) . Since these results could be explained on the basis of possible contamination of other "nonspecific" populations of cytotoxic cells, clone A15 was recloned . Unfortunately, our initial attempt to reclone A15 was unsuccessful .
Modulation of Cytotoxic Activities of the CTL Clones. The cytotoxic activities of all three clones against the autologous targets could not be modulated at the effector phase by autologous sera and autologous unactivated PBL (Table II) . The cytotoxic activities of the CTL clones against the corresponding autologous targets in the MC and PT systems were blocked by anti-CD3 mAb (data not shown) . In contrast, the cytotoxicity of the Tc1.8 (VIP system) was enhanced significantly by the anti-CD3 treatment. A more detailed analysis of anti-CD3-mediated enhancement of the cytotoxic function of CTL clone Tcl.8 has been communicated earlier (15) . Further, with reference to the restricted and broad target range of the CTL clones PT31 and A15, the roles of lymphocyte function-associated (LFA) antigen 1 and intercellular adhesion molecule (ICAM)-1 were examined . Table III shows that while the cytotoxic activities by A15 against the allogeneic targets were abrogated by anti-LFA-1 and anti-ICAM-1 antibodies, the same antibodies failed to block the cytotoxicity of A15 Percent specific lysis at E/T ratio is 20 :1 . Antigen Dependence, Life Span, and Stability ofthe CTL Clones . The CTL clones were restimulated every 1-3 wk with irradiated autologous melanoma cells (CTL/melanoma = 100:1) and, whenever available, with irradiated autologous PBL or with spleen cells in the PT system . This patient underwent splenectomy, which allowed us to freeze multiple vials of freshly isolated splenocytes . Despite repeated restimulation, the life span of all three CTL clones in continuous culture varied from 2 to 6 mo. At the end of their life span, the clones entered into "crises" leading to almost abrupt death. Restimulation at the crisis stage or the addition of higher dosages of IL-2, rIL-2, or rIL-4 seldom resurrected them .
Regulation ofCytotoxic Effector Response by T Cell Clones and Lines. The evidence for autologous tumor-specific downregulation of induction of cytotoxic response in autologous melanoma (10, 11) and in malignant paraganglioma (a tumor of neuroectodermal origin [13] ) has been published earlier. These studies were continued in order to further explore T cell-mediated regulation of cytotoxic responses in other systems. Fig. 6 shows three experiments in three separate systems in which the cytotoxic responses by the autologous PBL were regulated by three respective autologous CD4* T cell clones exhibiting CD3+, CD4+, and CD8-phenotypes . In the System MC System PJ System TF MC system, the CD4+ autologous clone, 15, upregulated the cytotoxic response. 15 was not cytotoxic against the autologous melanoma cells MC-M . In the other two systems (PJ and TF), the cytotoxic responses, regardless of the magnitudes of cytotoxicity, were markedly downregulated by the respective CD4+ T cell clones . In all three systems, the regulation by the T cell clones was observed in a dosedependent manner.
The amplification of cytotoxic response in the PBL induced by CD4+ T cell clones was observed in two other systems (systems DM andJC). In all three systems (MC, DM, and JC) the T cell clones exhibited the phenotype of "helper-inducer" cells (MY, CD4+, CD8-, 4114+, and 2H4-), and they amplified cytotoxicity in the PBL in IVC with the autologous melanoma cells in the absence of any exogenous IL-2 ( Fig. 6 and Table IV ). Table IV also shows that the amplification of cytotoxicity by the helper cell clones in the DM and JC systems could be blocked partially by anti-IL-2 antibody or by anti-IFN-y antibody. Table V shows examples of downregulation of cytotoxic responses in three separate systems and illustrates three specificity patterns ofdownregulation . In the MM system, the cytotoxic response by the PBL was signficantly suppressed by a CD4+ clone, MM T4. The suppression, however, was unrestricted as the cytotoxic responses against both the autologous and allogeneic targets (D/DR antigen-positive as well as D/DR antigen-negative) were suppressed . A similar pattern ofnonrestricted downregulation of cytotoxic response was observed in the CLB system in which a CD4+ T cell line, CLB Ts4 (expanded from a well seeded with 100 cells that grew vigorously in continuous culture for >2 mo), completely suppressed the induction of cytotoxic response by the autologous PBL against the autologous melanoma cells CLB-M and another allogeneic melanoma cell line . CLB Ts4 did not suppress cytotoxic response against a third melanoma cell line, PJ-M. It is noteworthy that the melanoma cells CLB-M and TFM expressed abundant D/DR II antigen, while the melanoma cell line PJ-M did not express any D/DR antigen. Interestingly, CLB Ts4 upregulated its Tac receptor when stimulated with the autologous and allogeneic targets expressing D/DR antigens and did not do so when stimulated with the D/DR antigen-negative target PJ-M (Fig. 7) . In both systems, the cytotoxic responses in the in vitro activa- tion cultures were quite modest . Even the modest cytotoxic responses were almost totally suppressed by the regulatory cells. CLB Ts4 were not cytotoxic for the autologous melanoma cells nor for several other melanoma targets (data not shown) .
In another melanoma system (GB), the CD4+ clone, GB 1.7, in contrast to the nonrestricted downregulation shown by the clones discussed earlier, downregulated the induction of cytotoxic response in a more restricted manner. The induction of cytotoxic response against allogeneic targets was minimally suppressed against one target and was not suppressed against the other (Table V) . In addition, coculture between GB PBL and GB 1.7 in the presence of the allogeneic target PTM (D/DR antigen-positive) or against PJ-M (D/DR antigen-negative) led to no suppression, or only marginal suppression, of cytotoxic response against the respective allogeneic targets (Table V) . Table VI shows an analysis of the characteristics of the 15 cases in which we were able to undertake a detailed functional analysis of such T cell responses. Interestingly, all the CTL clones in this study were CD8+ ; and all the regulatory clones exhibiting downregulation of CTL responses were CD4+ . An analysis of the magnitude of cytotoxic response by the activated PBL at population level (at the height of cytotoxic response, i.e., at 2 wk after initiation of the IVCs) and of the nature of the clonal responses revealed an interesting correlation. While CTL responses at clonal levels correlated with substantial cytotoxic responses by the corresponding activated PBL, the emergence ofdownregulatory responses was associated with very low cytotoxic responses by the corresponding activated PBL populations (Table VI) . In this analysis, the cytotoxicity values at 2 wk after the initiation of IVC were used for calculation of LU. 
Discussion
The results described here reaffirm earlier observations on CTL response against autologous melanoma from our laboratory (1) and other laboratories (2-4, 6, 7) . In addition to providing considerable credibility for the notion that true T cell effector response can indeed be demonstrated in autologous human melanoma, this study also supports the concept that cytotoxic effector response against autologous melanoma cells is subject to regulation by T cells. Besides providing support for these concepts, several interesting points have emerged from this study.
First, the T cell clones Tc1.8, MCC5, and PT 31 share characteristics that are exhibited by most bonafide CTL. All of them expressed restricted specificity; all demonstrated MHC class I-restricted function ; and they all used their TCR complexes one way or another. mAb to CD3 (a molecule associated with the TCR complex and quite possibly involved in signal transduction) blocked the cytotoxic function in two cases and enhanced cytotoxicity in the other. It is ofinterest to note that, although the cytotoxicity of Tc1.8 was enhanced by the treatment with CD3 mAb, Tc1.8 needed the full expression of the receptor complex for its function, since modulation of the complex completely abrogated such function (15) .
Second, the burdensome demands both of effort and of time involved in carrying out a completely satisfactory and thorough functional analysis of hundreds of emerging clones in individual systems do not allow a credible estimate of the frequency of CTL response in patients with advanced disease. It should be noted that, although we isolated true CTL clones demonstrating specificity in limited cases only, we were able to generate cytotoxic responses at population levels against the autologous melanoma cells in IVC in the majority of these patients . Even if the cytotoxic responses induced in IVC in the other systems reflected lymphokine-activated killer cell-type responses and/or NK cell-type responses, it is quite clear that we were not always successful in selecting true CTL clones in other systems. In this context, it should be mentioned that in the PT system, the MHC class I-restricted autospecific CTL clone PT 31 was isolated in our second attempt. In another system (system AS), although we were able to demonstrate MHC class II-restricted melanoma-specific CD4+ CTL response at the population level (data not shown), we failed to isolate an MHC class II-restricted CD4+ CTL clone from a total of 60 expanded and wellstudied CD4+ clones from two separate clonings of 2,000 cells. Thus, these types of technical uncertainties and difficulties in obtaining CTL clones might account for an observed low CTL frequency in advanced melanoma.
Third, our data clearly demonstrate that a CTL clone demonstrating a wide target range, or "promiscuous" cytotoxic behavior, may also exhibit antigenic specificity. Although we cannot rule out the possibility that the CTL clone PT A15 did not have another irrelevant population(s) of cytotoxic cells, the cold target competition experiments with A15 and the relevant autologous and irrelevant allogeneic targets (Fig . 5) clearly ruled out antigenic similarities between the autologous and allogeneic targets. Thus, in reference to cytotoxicity against the irrelevant allogenic targets, clone A15 could have been activated through interactions of accessory molecules and their respective ligands on the target cells. Hence, the possibility exists that a bonafide CTL clone can be activated through alternate activation pathways (i .e ., CD2-LFA-3 or through other homotypic and/or heterotypic adhesion molecules that may also serve in signal transduction). Indeed, the cytotoxicity against the irrelevant allogeneic targets by CTL clone A15 could be substantially blocked by mAbs against LFA-1 and ICAM-1, while the cytotoxicity of A15 against the autologous melanoma cells was not blocked. Similarly, cytotoxicity of PT 31 against the autologous PTIM melanoma cells also was not blocked by these reagents (Table III) . Fourth, frequent restimulation by the appropriate antigen and/or autologous accessory cells was not enough to maintain these clones indefinitely in continuous culture . A different strategy, namely, the insertion of a different growth factor gene or a growth factor receptor gene, such as has been accomplished recently by Pierce et al . (16) , or the induction of immortality through infection or transfection by a suitable retroviral transforming gene, needs to be considered .
Last, it is clear that once the CTL are activated and amplified, their cytotoxic function cannot be blocked at the effector phase by autologous PBL or by autologous sera . Since the fresh PBL and LNL (from which the CTL clones were obtained) were not cytotoxic against their respective autologous melanoma cells, even though a CTL clone(s) could be isolated from its in vitro activated counterparts, one might argue that the cytotoxic unresponsiveness in the fresh effector population was not due to "clonal deletion ." Alternatively, such cytotoxic unresponsiveness might have been a reflection of their numeric insufficiency or of the lack of "help" required for activation and amplification of T cell response . It might have resulted also from the influence of the regulatory apparatus.
In reference to regulation of antitumor CTL response, although the role of "suppressor cell activity" has received considerable attention (17, 18) , the authenticity of the phenomenon has only been established in the animal tumor system (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Earlier, we presented the evidence of T cell-mediated downregulation of cytotoxic response in two human systems (10, 11, 13) . More recently, Cozzolini et a1 . (29) also have presented indirect evidence of suppressor cell activities in proliferative T cell response in tumors of the head and neck region . Further, Livingston et al . (30) have shown cyclophosphamide-sensitive suppressor cell activities in patients with melanoma . Clearly, then, the issue of cell-mediated suppression of immune response to human tumors has assumed more relevance.
From the above perspective, the present study provides several noteworthy points . First, our data provide additional support for the view that cell-mediated effector response against autologous human cancer is subject to both up-and downregulation . The upregulation of cytotoxic response in coculture induced by the CD4+ helper or "helper-inducer" clones in the MC, DM, andJC systems (Fig . 6 ) is similar to one of our earlier observations (13) . It appears that the amplification of cytotoxic response in the PBL in IVC by the helper cell clones was mediated primarily by IL-2 and by IFN--y (Table IV) . Since these cytokines can influence the behavior of a diverse group ofimmunocompetent cells (e.g., CTL, LAK, NK, and effector macrophages), these Th cells, therefore, can exert a broad range of regulatory influences . It is noteworthy that, in the MC system, we were also able to document a CTL response (Fig. 3) .
Second, the cells participating in downreguaatory activities are predominantly CD4' T cells. It is unclear, presently, whether these CD4+ regulatory T cells act as suppressor effector cells themselves or act as intermediaries (suppressor inducers). In an earlier communication (11) we demonstrated that CD4+ T cells can, indeed, induce a CD8' suppressor effector population .
Third, the regulatory process includes autorestricted as well as nonrestricted interventions. The autorestricted downregulation by the CD4' clone GB 1.7 of cytotoxic immune response in the GB systems is reminiscent of similar autorestricted downregulations shown earlier in two other autologous human tumor systems (10, 11, 13 ). Further, the higher level of downregulation induced by the T cell clone GB 1 .7 against the autologous target was not due to differential expression of D/DR antigen between the melanoma cells GB-M and PTM. In fact, the autologous melanoma cells GB-M expressed D/DR antigen quantitatively at a lower level than did the PTM cells (data not shown) . Additional evidence for autologous melanomaassociated specificity of the regulatory T cell clone GB 1.7 has been observed . For example, the GB 1.7 cells selectively upregulate their Tac receptors when they are stimulated by the autologous melanoma cells GB-M; and they proliferate when stimulated by the melanoma cells GB-M and exogenous IL-2 (N. G. Chakravorty, and B. Mukherji, manuscript submitted for publication) .
Fourth, it is clear that the nonselective downregulation of cytotoxic immune response by CD4' T cell clones in the melanoma system may represent regulation resulting from interaction with the D/DR antigen. The interactions between the PBL and the MHC class II-bearing melanoma cell CLB-M led to a CD4+ T cell response that profoundly suppressed cytotoxic responses against both the autologous and allogeneic melanoma targets (Table V) . This is analogous to autologous mixed lymphocyte reaction (AMLR), which may lead to downregulation ofimmune response in different assay systems (31, 32) . All nonrestricted downregulations seen in our study, however, did not represent similar situations as evidenced by the nonrestricted downregulation against D/DR antigen-negative allogeneic target shown in the MM system (Table V) . The D/DR antigen-induced regulation, nevertheless, is quite intriguing, considering that a significant percentage of human melanomas constitutively express D/DR antigens (33) . D/DR antigens have been shown to play a regulatory role in T cell proliferative responses against melanoma cells (34, 35) . From an operational point of view, whatever molecular specificities the regulatory cells recognize ("tumor antigen," D/DR antigen, or some other specificity), when such recognition leads to suppression of CTL response, the phenomenon assumes considerable significance in the context of immune response to human melanoma. Interestingly, in this group of patients the emergence of a regulatory response in our in vitro cocultures was associated with only a modest cytotoxic response in the effector populations (Table VI) .
Finally, it is of interest that, in our group of patients, identical in vitro activation techniques led to the CTL responses, in some, and regulatory responses (specific or nonspecific), in others, without any discernable correlation with GD3, GM2, or D/DR antigen expression by the respective melanoma cells (cumulative data not shown) . Circumstances leading to these two opposite results (CTL vs. regulatory response) remain unclear. In this context, it should be noted that immune responses in the chemically induced tumor system in animals have been known to go through sequential expression of CTL responses followed by the emergence of regulatory responses (18, 26) . Careful analysis of immune responses in patients with primary melanomas and sequential analysis of immune responses in a group ofpatients over a length of time will provide much insight into this issue. Summary T cell-mediated immune response against autologous melanoma cells was analyzed, at population and clonal levels, in 31 patients with recurrent and/or metastatic disease. Fresh PBL and lymph node lymphocytes (LNL) from melanoma-involved nodes were not cytotoxic against the respective melanoma cells . When activated in in vitro coculture (IVC) against the autologous melanoma cells in the presence of IL-2, a majority ofthe activated PBL and LNL became cytotoxic against the autologous targets. The activated effector cells were cloned in limiting dilution microcultures, and growing clones were phenotypically defined and were functionally characterized for cytotoxicity and for potential regulatory function .
Functional T cell clones were obtained from 15 of 31 cases. Of these, CTL responses exhibiting cytotoxicity restricted against the autologous melanoma were seen in four cases. All four CTL clones were CD3', CD8+, and CD4`. Three of these four CTL clones were studied extensively. All three of these CTL clones expressed MHC class I-restricted cytotoxicity. mAb anti-CD3 blocked cytotoxicity in two and enhanced cytotoxicity in the other. Neither autologous sera nor autologous nonactivated fresh PBL modulated the cytotoxic functions ofthe CTL clones at the effector phase. T cell lines exhibiting regulatory function were obtained in 11 cases. The regulatory T cell lines were CD3+ , CD4+ , and CD8-. In three cases CD4+ clones amplified the cytotoxic response in the PBL in coculture, while in eight other cases the T cell lines downregulated the cytotoxic responses. Such T cell-mediated downregulations were either restricted to the autologous system, induced by D/DR antigens expressed by the autologous or allogeneic melanoma cells, or induced by stimulus other than D/DR antigens . Taken together, these findings clearly demonstrate the existence of T cell-mediated cytotoxic and regulatory responses against human melanoma.
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